news
Press release
 
February 22, 2016
CorPath System to be Highlighted at 2016 Cardiovascular Research Technologies Meeting

Groundbreaking Masters in Transradial Intervention session and podium talks feature robotics for PCI and highlight the CorPath System

WALTHAM, MA - FEBRUARY 22, 2016Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that it will provide hands-on demonstrations of complex robotic-assisted percutaneous coronary intervention (PCI) using the CorPath® System at the 2016 Cardiovascular Research Technologies (CRT) meeting to be held in Washington, DC on February 20-23. CRT is a comprehensive interventional cardiology conference that attracts more than 2,000 interventional and cardiovascular specialists.

  • "Robotic PCI: Practical Considerations for Adoption of Robotics in Your Cath Lab," a presentation by Dr. Ryan Madder of Spectrum Health taking place on Tuesday, February 23 at 8:50 a.m.
  • "Robotically-assisted Peripheral Vascular Intervention," * a presentation by Dr. Ehtisham Mahmud, Division Chief of Cardiovascular Medicine, Director of the Sulpizio Cardiovascular Center and Interventional Cardiology at UC San Diego taking place on Tuesday, February 23 at 9:00 a.m.
  • Participation in the Masters Transradial Intervention Course, a first-of-its-kind course dedicated to bringing together industry leaders to discuss the advancements of radial access adoption in the U.S. Corindus is a sponsor of the event along with a small group of other industry leaders.

"I am excited about the partnership between Corindus and CRT," said Ron Waksman, MD, CRT 2016 Course Chairman. "I know first-hand about the benefits of the CorPath System, and count myself among the pioneers who brought this technology to MedStar Washington Hospital Center. It is important that physicians understand their need for protection in the cath lab, and that the CorPath System can be a solution to risks they face on a daily basis."

For the first time, the CRT conference features a special transradial intervention master’s course. Radial access is widely considered the standard of care outside the U.S. and, while data has shown that it improves clinical outcomes by reducing PCI-related complications for the patient, it is also known to increase radiation exposure to the operator.

"Radiation exposure protection provided by the CorPath System becomes increasingly important as more physicians adopt radial access as a standard practice," said David Handler, President and CEO, Corindus. "We are excited to participate in the radial master’s course and look forward to highlighting CorPath robotic-assisted PCI at CRT, a conference that brings the latest clinical research and technological advancements to the interventional community."

Attendees can participate in hands-on demonstrations of the CorPath System with an advanced simulator at CRT at Corindus Vascular Robotics Booth #103. For additional information, visit www.corindus.com, and follow @CorindusInc.

*The CorPath 200 System has not been cleared for use in Peripheral Vascular Interventions by the FDA. Corindus, Inc. sponsored the RAPID Trial.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window
Thank you for subscribing to our newsletter. You will now receive email updates from Corindus.